PGEN Stock Analysis: Buy, Sell, or Hold?
PGEN - Precigen, Inc. Common Stock
$4.21
0.06 (1.45%)
▲
5d:
+3.19%
30d:
-1.41%
90d:
-1.86%
BUY
HIGH Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 13, 2026
2d
Smart Money Distribution
PGEN is up 6.8% this week, but smart money is buying puts. Top strike: $3 2026-07-17 with 15,090 OI. Put ratio: 89% View Scanner →
Strength: 7.3/10
Get Alerted When PGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PGEN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: PGEN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: PGEN is currently trading at $4.21, which is considered slightly high relative to its 30-day fair value range of $3.85 to $4.25. The stock's valuation (Forward PE: 76.5) is in line with its historical norms (74.5). At these levels, the market is pricing in 0.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PGEN is in a strong uptrend. Immediate support is located at $3.92, while resistance sits at $4.41.
Market Sentiment: PGEN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.50 (+125.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PGEN is in a strong uptrend. Immediate support is located at $3.92, while resistance sits at $4.41.
Market Sentiment: PGEN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.50 (+125.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.85 -
$4.25
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 125.7% below Wall St target ($9.50)
- NEUTRAL: Market pricing in 0.9% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$3.85 -
$4.25
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.92
Resistance Level
$4.41
Current Trend
Strong Uptrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
76.55
Wall Street Target
$9.50
(+125.7%)
Revenue Growth (YoY)
283.6%
Valuation Premium vs History
+0.9% premium
PE vs Historical
76.6 vs 74.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.9%
(market-implied from PE analysis)
1-Year Target
$4.25
(+1%)
2-Year Target
$4.29
(+2%)
3-Year Target
$4.32
(+3%)
3-Yr Target (if PE normalizes)
(PE: 77→75)
PE COMPRESSION
$4.21
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: May 10, 2026 3:10 PM ET
Data refreshes hourly during market hours. Next update: 4:10 PM
Data refreshes hourly during market hours. Next update: 4:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Randal J Kirk
SELL
4772781 shares
2026-03-30
Randal J Kirk
SELL
1900036 shares
2025-12-22
Randal J Kirk
SELL
937308 shares
2025-11-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 57 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 69 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 58 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 56 HOLD |
Advanced PGEN Option Strategies
Professional options setups generated by AI based on today's PGEN price and gamma walls.
